Mohamad Salkeni, MD
Hematology & Oncology · Fairfax, VANPI 1265635924
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,130 of the $11,557 with a category attached, or 79.0%. 19 manufacturers reported payments, led by Daiichi Sankyo Inc. at 30.5% of the total. 2025 is the largest year on record at $8,199, 6.5 times the $1,270 reported in 2019.
Across 31 payments — averaging $372.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$4K
- AbbVie$3K
- AstraZeneca$3K
- Pfizer$1K
- Array Biopharma Inc$49
- Genmab U.S., Inc.$35
- plus $261 from 13 others
Across 279 payments — averaging $7195.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$498K
- Exelixis Inc.$437K
- Daiichi Sankyo Inc.$315K
- Boehringer Ingelheim$161K
- Chugai Pharmaceutical Co., Ltd.$148K
- Beigene, Ltd.$101K
- plus $347K from 11 others
What the payments were for
- Consulting fees$9,13079%
- Speaking & faculty fees$1,27011%
- Travel & lodging$5425%
- Food & beverage$5885%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 3 | $3,525 |
| AbbVie | 8 | $3,212 |
| AstraZeneca | 2 | $3,205 |
| Pfizer | 2 | $1,270 |
| Array Biopharma Inc | 2 | $49 |
| Genmab U.S., Inc. | 1 | $35 |
| Pharmaessentia USA Corporation | 1 | $32 |
| Bayer | 1 | $30 |
| Coherus Oncology, Inc. | 1 | $27 |
| Sanofi | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Deciphera Pharmaceuticals Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| GSK | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Seagen Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,557 in reported general payments places this provider in the 85th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Granisetron Hcl | 14 | $984 |
| Metronidazole | 19 | $857 |
| Doxycycline Hyclate | 22 | $672 |
| Triamcinolone Acetonide | 18 | $263 |
| Hydroxyzine Hcl | 11 | $74 |
| Prednisone | 13 | $22 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Fairfax
- William ErshlerFairfax$139K
- Sekwon JangFairfax$56K
- Raymond WadlowFairfax$30K
- Daniel ChongFairfax$15K
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.